Technology, Patents, and Sport

​
May 13, 2026

This summer, on June 11, the opening game of the FIFA World Cup 2026 is set to take place. Due to an expansion of the number of teams, this will be the largest edition of the tournament so far, involving 48 nations (with England, Germany, Sweden, and the USA providing representation for almost all EIP branches). An enormous number of eyes will be focused not only on some of the world’s most talented athletes, but also—albeit perhaps unintentionally—on the technology behind modern sport. From the equipment to the refereeing, innovation and technology play a crucial role in the world of football, and in sport generally. This article will explore the roles of patents and intellectual property protection in the modernization of sport.

Why "IP and Sports" became a global theme

Each year, the World Intellectual Property Office (WIPO) organizes World IP Day, and this year the theme was: “IP and Sports: Ready, Set, Innovate”. The emphasis on intellectual property as a driver of creativity, innovation, and development in the sporting world is understandable given the expanding role of technology across various aspects of most sports. It is not only about using the latest technology to be competitive at the highest level, but also about increasing fairness in rule enforcement, and improving the experience of the viewers.  

On the pitch: VAR, goal-line technology, and AI player avatars

In football especially, the introduction of technology as a means for assisting the referees has been received with varying degrees of enthusiasm, to say the least. While there are valid reasons for criticizing the way of implementing technologies such as goal-line technology (GLT), Video Assistant Refereeing (VAR), and semi automated offside technology (SAOT), these developments illustrate the technological aspect of football. This summer, the World Cup will also implement AI enabled 3D player avatars, created through body scans of the players, to further enhance the SAOT system. As the technologies develop, the challenge and opportunity will be to deploy them in ways that strengthen officiating accuracy, while preserving the passion and emotions that define the sport.

However, these technologies will not improve organically or in isolation. Improvements are the results of research and development, significant investment, and close collaboration between engineers, entrepreneurs, sport associations, and broadcasters, which is where intellectual property comes in. Developing reliable systems for real‑time sensing, imaging, and data processing requires long development projects and substantial resources, often with no guarantee of immediate success. In this context, patent protection plays an important role by providing inventors and companies with the confidence to invest in innovation, share technology, and continue refining solutions that can improve both the accuracy and the overall experience of the game.

As sport continues to modernize and becomes increasingly technological, the importance of patents and other intellectual property rights grows. Clubs and players across all sports rely heavily on advanced equipment, sensor systems, and data-driven platforms to collect player statistics and performance metrics, allowing for workload analysis, training optimization, and injury risk reduction. These examples include wearable tracking systems used by elite clubs to monitor player workload, and injury prediction platforms, which are both dependent on patented technical solutions. The development and refinement of such technologies, as well as access to the latest solutions, can therefore have a direct impact on player performance, availability, and long term health. As the demand for continued innovation grows, the need for effective patent protection and a thoughtful IP strategy in the sporting world may increase even further.

A patent strategy that keeps pace with the game

In elite sport, as in many other fields, innovation increasingly determines success. Patents and other intellectual property rights constitute a framework for turning technological advances into reliable solutions, and helping to ensure that innovation not only continues, but continues to improve outcomes for fairness, performance, and player welfare. While it may be more captivating to focus on the teams, goals, and winners this summer, one may also consider admiring the innovation and technological development behind the world’s biggest sporting event. From an IP perspective, sport offers an example of how a successful patent strategy actively supports progress, and at EIP we are well prepared to assist with IP matters across all sectors, sport included.

‍

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​